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Background: Tofacitinib (TFC) is an oral, small-molecule Janus 
kinase inhibitor, which was recently approved for moderate to se-
vere ulcerative colitis (UC). The aim of the current real-life study 
was to determine efficacy of TFC induction therapy regarding the 
clinical response and remission in patients with active UC. We eval-
uated short-term efficacy data in a Hungarian cohort with prior 
exposure to other biological agents such as anti-TNF drugs and 
vedolizumab.
Methods: In this single-centre retrospective study, patients with 
TFC introduction were included. Since January 2019, a total of 
16 patients received an oral TFC induction therapy in a dose of 
10 mg twice daily for 8 weeks. Endoscopic activity was evalu-
ated by endoscopic Mayo (eMayo) score before the introduc-
tion of TFC and in case of an inadequate therapeutic response 
to the 5-mg-therapy to confirm therapeutic decision-making. 
Based on the evaluation of clinical symptoms and laboratory 
parameters, we either kept the dosage or reduced the dose to 
5  mg according to local regulations. We also collected data 
from the 16. and 24. weeks of the therapy. Primary endpoints 
were a clinical response (as a reduction in partial Mayo Score 
[pMayo] by minimum 3 points) or remission (as a Mayo score 
of the maximum of 2 points and without blood in stool) at 
week 8.
Results: Sixteen patients had received the induction therapy (mean 
age: 36 years, 7 males and 9 females) in our centre. After 8 weeks, 
12 (75%) patients responded to the TFC induction therapy and 6 
(37.5%) of them were in remission. Four patients were primary non-
responders (25%). Corticosteroid therapy (18 ± 7 mg) was required 
during the induction in 4 responder cases, which could be stepped 
down by week 8. As a continuous maintenance therapy, 4 patients 
have already reached the 16th week and 8 have completed the 24th 
week. By the end of the follow-up, 12 patients responded and 10 
was in remission. During the observation period, 3 patients had to 
remain on 10 mg TFC dose, 6 patients required dose escalation from 
5 mg to 10 mg and 5 mg was sufficient in case of only 3 patients after 
the introduction. Endoscopic activity showed a moderate decrease 
from 2.5 ± 0.5 eMayo score to 2 ± 1 (n = 7) until week 16. In respect 
the responder patients, CRP levels decreased from the mean of 7.23 
to 5.02. No serious side-effects were observed during the follow-up.
Conclusion: After the 8-week TFC induction therapy, the response 
rate was high and only every fourth patients were non-responder. 
A low number of patients had adequate reactions to the 5 mg-ther-
apy after the introduction, but TFC is effective with dose-escalation 
in respect of clinical response and remission in patients with UC, 
who have had an inadequate response to previous biological therapy.
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Background: Vedolizumab (VDZ), a gut-specific anti-integrin, is 
approved as a treatment for moderate to severe Crohn’s disease (CD) 
and ulcerative colitis (UC). Extra-intestinal manifestations (EIMs) 
are frequently associated with inflammatory bowel disease (IBD). 
However, the effect of VDZ on EIMs remains unknown. The aim 
of the current study was to describe the prevalence of EIMs in IBD 
patients at VDZ initiation, the evolution during continued treatment 
as well as the occurrence of new EIMs.
Methods: A single-centre study was performed in IBD patients 
who were started on VDZ between May 2010 and February 2019. 
Retrospectively, the physician-reported EIMs and intestinal disease 
activity (clinical and endoscopic) were assessed at baseline, 6 months 
and 1 year after the start of VDZ.
Results: The cohort consisted of 134 patients, including 77 CD 
patients, 56 UC patients and 1 patient with unclassified IBD. At 
VDZ initiation EIMs were assessed in 127 patients and 17.3% had 
≥ 1 EIM: 9 hepatic EIMs (2 patients with toxic hepatitis, 2 with 
autoimmune hepatitis and 5 with PSC), 7 arthropathies (6 patients 
with axial spondyloarthropathy and 1 with peripheral arthritis), 
3 non-further specified axial or peripheral arthralgias and 3 cuta-
neous EIMs (urticaria, psoriasis and erythema nodosum). Clinical 
evolution of the EIMs is reported in Table 1, assessment of intes-
tinal disease activity in Table 2.  During follow-up, 23 new EIMs 
were seen, mainly arthralgia, which was often transient. VDZ was 
stopped in 39/130 (30%) patients due to active intestinal disease in 
32 patients, patients’ choice (n = 1) or because of deep disease remis-
sion (n = 1). In five patients, VDZ was stopped because of insufficient 
control of EIM.
Table 2. 
Clinical, n (%) 6 months (n = 109) 1 year (n = 106) 
No response 13 (11.9) 10 (9.4) 
Response 34 (31.2) 24 (22.6) 
Remission 62 (56.9) 72 (67.9) 
Endoscopic, n (%) Post induction (n = 81) 1 year (n = 44) 
No response 24 (29.6) 12 (27.3) 
Response 35 (43.2) 7 (15.9) 
Remission 22 (27.2) 25 (56.8) 
Conclusion: A good clinical intestinal response was observed. 
However, the clinical evolution of EIMs appears unaffected by the 
use of VDZ in our cohort. Prospective data are needed to confirm 
these results.
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Background: Anti-TNF antibodies treatments are the only first-line 
reimbursed biologics for Crohn’s disease (CD) in several countries. 
Recently, Vedolizumab (VDZ) and Ustekinumab (UST) were added 
to the therapeutic armamentarium for CD refractory to a first anti-
TNF antibody. However, studies comparing these two compounds 
remain unavailable. Our aim was to compare their efficacy in sec-
ond-line treatment in CD after failure of one TNF antagonist.
Methods: All patients with CD refractory (primary or secondary 
non-responders) to first anti-TNF treatment and receiving UST or 
VDZ as a second biologic were included retrospectively in 10 French 
tertiary centres. The remission and clinical response were assessed at 
week 14. On the long-term, the cumulative probabilities of being in 
remission were estimated using the Kaplan–Meier method and the 
associated factors using a Cox proportional risk model. The drug 
survival to assess efficacy as well as side effects was assessed by ac-
tuarial analysis.
Results: 88 patients were included, 50 (57%) females (mean age: 
41 ± 15 years), 61 (69%) being treated with UST and 27 (31%) with 
VDZ. The first anti-TNF was discontinued for primary or secondary 
non-response in 66 (75%) patients and for side effects in 22 (25%) 
patients, without any difference between the anti-TNF antibody pre-
viously used. Among the 55 patients with endoscopic data at base-
line, 55 (98%) had ulceration, a CRP above 5mg/l for 33/71 (46%) 
patients and a faecal calprotectin > 250 µg/g for the 12 patients tested. 
At week 14, no difference was observed for clinical response and clin-
ical remission according to the type of treatment: the rate of clinical 
response and remission were 74% (UST)/58% (VDZ) (p = 0.20) and 
33% (UST)/26% (VDZ) (p = 0.56), respectively. The only factor asso-
ciated with short-term remission was the lack of optimisation prior to 
anti-TNF discontinuation (p = 0.038) regardless of the type of second-
line therapy (UST, p = 0.02; VDZ, p = 0.03). After a mean follow-up 
of 67 weeks, the cumulative probabilities of being in remission at 6 
and 12 months were 16% and 34% for UST and 25% and 44% for 
VDZ, respectively (p = 0.24 for UST vs. VDZ). The drug survival was 
higher in the UST group as compared with the VDZ group (HR (UST 
vs. VDZ) = 2.36 [1.02–5.5], p = 0.04).
Conclusion: Our preliminary results suggest that VDZ and UST 
have similar efficacy in the short- and long-term response when used 
as a second-line biologic therapy in CD refractory to a first anti-TNF 
antibody. These results will be complemented for the congress by the 
inclusion of additional patients recruited into this registry.
P666
Neutropenia in inflammatory bowel disease 
patients on TNF inhibitors: A single-centre, 
retrospective cohort study
D. AlAskar, A. Mais, E. Al Sulais, T. Alameel*
King Fahad Specialist Hospital Dammam, Medicine, Dammam, 
Saudi Arabia
Background: Tumor necrosis factor-α inhibitors (TNFi) have be-
come the mainstay of treatment in moderate to severe cases of IBD.
The haematological safety profile of these agents has been docu-
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